|
|
|
|
|
Cevimeline
drug data and news
Cevimeline drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Cevimeline | ||
| Brand Names/Synonyms | AF 102B; AF-102B; Cevimeline; Cevimeline Hydrochloride; Cevimeline Hydrochloride Hydrate; Cevimeline, Hydrochloride Salt; Cevimelinehydrochloride Salt; Evoxac; Fks 508; Sni 2011 | ||
| Indication | For the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Cevimeline is a cholinergic agonist which binds to muscarinic receptors. Cevimeline is indicated for the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome. | ||
| Mechanism Of Action | Muscarinic agonists such as cevimeline in sufficient dosage can increase secretion of exocrine glands, such as salivary and sweat glands and increase tone of the smooth muscle in the gastrointestinal and urinary tracts. | ||
| Cevimeline News (When available) |
| ||
| Dosage Forms | Not Available | ||
| Drug_Category | Parasympathomimetics; Muscarinic Agonists | ||
| Absorption | Rapidly absorbed with peak concentration after 1.5 to 2 hours | ||
| Interactions |
Interactions for Cevimeline: Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances. Drugs with parasympathomimetic effects administered concurrently with cevimeline can be expected to have additive effects. Cevimeline might interfere with desirable antimuscarinic effects of drugs used concomitantly. Drugs which inhibit CYP2D6 and CYP3A3/4 also inhibit the metabolism of cevimeline. Cevimeline should be used with caution in individuals known or suspected to be deficient in CYP2D6 activity, based on previous experience, as they may be at a higher risk of adverse events. In an in vitro study, cytochrome P450 isozymes 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 were not inhibited by exposure to cevimeline. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine | ||
| Chemical Formula | C10H17NOS | ||
| Molecular Weight | 489.565 g/mol | ||
| Smiles String | CC1OC2(CN3CCC2CC3)CS1 | ||
| Melting Point | 201-203 oC (HCl salt) | ||
| Water Solubility | Very soluble | ||
| State | Solid | ||
| LogP/Hphobicity | Not Available | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Primarily hepatic by CYP2D6 and CYP3A4. 45% of dose is converted to cis and trans sulfoxides and 25% is converted to the glucuronic acid conjugate | ||
| Half Life | 5 +/-1 hours | ||
| Protein Binding [%] | <20% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Cevimeline.html http://www.rxlist.com/cgi/generic2/cevimeline.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00224 | ||
| CAS Registry Number | 107223-08-9 | ||
| KEGG Compound ID | C07772 | ||
| PubChem ID | SID:9974 | ||
| PharmGKB ID | PA448916 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |